Gunilla Ekstrom - Karolinska Development Insider

Karolinska Development AB -- Sweden Stock  

SEK 6.05  0.1  1.63%

Vice President - Operations

Dr. Gunilla Ekstrom was Vice President Operations at Karolinska Development AB since June 2012. Gunilla Ekstrom has over 20 years of experience from senior positions in the pharmaceutical industry including as Senior Vice President at Orexo AB and Global Product Director at AstraZeneca RD. She is also Board member of Athera Biotechnologies AB Biosergen AS Inhalation Sciences Sweden AB Lipidor AB NovaSAID AB Pharmanest AB and CEO of Biosergen AS. She holds Doctorate of Medicine and Doctorate in Philosophy degrees and is Associate Professor at Karolinska Institutet.
Age: 54  President Since 2012  Ph.D    
46 8 52 48 60 70  http://www.karolinskadevelopment.com

Management Efficiency

The company has return on total asset (ROA) of (4.21) % which means that it has lost $4.21 on every $100 spent on asset. This is way below average. Similarly, it shows return on equity (ROE) of (156.17) % meaning that it generated substantial loss on money invested by shareholders.
The company has accumulated 357.55 M in total debt with debt to equity ratio (D/E) of 868.2 indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Karolinska Development AB has Current Ratio of 24.99 suggesting that it is liquid and has the ability to pay its financial obligations in time and when they become due.

Similar Executives

Found 5 records

PRESIDENT Since

Kristoffer HanssonBioInvent International AB
2016
PerAnders JohanssonBioInvent International AB
2014
Martin WilesBioInvent International AB
N/A
Trevor JuniperBioInvent International AB
N/A
Bjorn FrendeusBioInvent International AB
N/A

Entity Summary

Karolinska Development AB is a VC firm specializing in investments in growth capital, seed stage, and early stage companies. Karolinska Development AB (KDEV) is traded on Stockholm Stock Exchange in Sweden. It is located in Solna, and employs 13 people.
Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations when you add Karolinska Development AB to your portfolio

Top Management

Karolinska Development AB Leadership Team
Hans Wigzell, Chairman, Ph.D
Elisabet Gimbringer, Executive
Carl Sundberg, Director
Magnus Persson, Director, Ph.D
Jim Heusden, CEO, Ph.D
Maria Ferm, Executive
HansOlov Olsson, Director, Ph.D
Viktor Drvota, Executive, Ph.D
Eva Montgomerie, Executive
Michael Owens, Executive
Yan Cheng, President
Ulf Richenberg, Executive
Niclas Adler, Director
Tse Ping, Director, Ph.D
Christian Tange, CFO, MBA
Daniel Bolanowski, Executive
Terje Kalland, Executive, Ph.D
Vladimir Artamonov, Director, MBA
Felicia Rittemar, Executive
AnnSofie Sternas, President
Anders Harfstrand, Director, Ph.D
Bo Hansen, Chairman, Ph.D
Viktor MD, Executive
Khalid Islam, Director, Ph.D
Gunilla Ekstrom, President, Ph.D
Henrijette Richter, Director

Stock Performance

Karolinska Development Performance Indicators